logo-loader
viewImmuPharma PLC

ImmuPharma's Tim McCarthy details Lupuzor licensing deal with Avion Pharmaceuticals

ImmuPharma PLC's (LON:IMM) chairman Tim McCarthy caught up with Proactive's Andrew Scott to talk through the recently announced licensing deal worth almost US$100mln for Lupuzor -  its treatment for the autoimmune disease lupus.

US speciality drugs group Avion Pharmaceuticals will fund the US$25mln costs of a phase III clinical trial next year.

Quick facts: ImmuPharma PLC

Price: 14.556 GBX

AIM:IMM
Market: AIM
Market Cap: £24.36 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ImmuPharma: Analyst discusses 'impressive and potentially blockbuster' ...

The Life Sciences Division's Navid Malik gives his view on the recent recent deal ImmuPharma PLC (LON:IMM) struck with US speciality drugs group Avion Pharmaceuticals. Malik reckons its lupus candidate Lupuzor could become a 'US blockbuster' by generating over US$1bn revenues per year.

on 16/12/19

2 min read